Tiberias HK | IVD | GI Cancer | Sub. ArbeleBio

Tiberias Technology, founded in 2016,
is the sister company of Arbele Limited

Both are subsidiaries of Arbele Investment Limited. While Arbele Limited works on the development of first-in-class immunotherapeutics for Gastrointestinal (GI) cancers, Tiberias focuses on the research and development of novel In-Vitro Diagnostic (IVD) platforms for GI cancer detection and management. Our ultimate goal is to develop and commercialize highly sensitive and specific IVD products that will support clinical and personal decision making in patients with GI diseases.

In-Vitro Diagnostic

Innovative IVD platforms powered by data-driven research for accurate detection of GI cancer-specific biomarkers — enabling early diagnosis, improved patient monitoring, and scalable mass screening to boost survival rate and population health.

Tender Invitation

Manufacture Monoclonal Antibody (mAb) for our IVD Pipeline

Apr 2021

Anti-CDH17 Abs NMPA Class 1 Registration

July 2021

TD New Lab Establishment (HK)

Apr 2022

ISO 9001:2015 Accreditation (TDx)

June 2022

ARB202 CDH17 (TIB-17C) Pre-screening (FPI)

Dec 2022

TibTech IHC Method filed for Provisional PCT

Apr 2023

ASCO 2023 – New TDx and BDx data acceptedfor publication

Jul 2023

ISO9001-2015 Service Scope Extension (TDx and BDx)

Jan 2024

Claudin 18.2 IHC Service Launch (Collaboration with AMDL)

Apr / Sep 2024

AACR 2024 Poster Abstract Presentation ESMO 2024 Congress

Oct 2024

Enter Strategic Collaboration with BioAI

Dec 2024

ESS Funding Approval*

HK$3,350,250

* B/E011/24 Development of In-Vitro Companion Diagnostic targeting CDH17 for guided precision and persaonalized medicine for Gastrointestinal Cancer

Jan 2025

HKMA/HKT Global Innovation Award 2024/25 - Silver Award

Publications

Diagnostic and prognostic applications of blood Cadherin-17 (CA17) and CA19.9 on Pancreatic cancer
Accepted for ASCO 2025 annual meeting online publication (abstract no.:505802)

Diagnostic and prognostic application of blood and tissue cadherin-17 biomarker in pancreatic cancer
Accepted for AACR 2025 annual meeting poster presentation (abstract no.:7068)

Development of a Cadherin-17 (CDH17) Immunohistochemistry Assay for Use as a Companion Diagnostic for Cabotamig in Gastrointestinal Cancers
Accepted for ESMO 2024 annual meeting poster presentation (abstract no.:183)

Diagnostic application of a novel blood CDH17 immunoassay in the detection of colorectal adenoma
Accepted for AACR 2024 annual meeting poster presentation (abstract no.:1061)

Diagnostic application of circulating CDH17 biomarker for screening GI malignancies.
Accepted for ASCO 2023 annual meeting poster presentation (abstract no.:3058)
Tissue cadherin 17 (CDH17): A favorable prognostic determinant of colorectal cancer using digital image analysis.
Accepted for ASCO 2023 annual meeting online publication (abstract no.:e14651)
The diagnostic significance of CDH17-positive circulating tumor cells in patients with colorectal cancer
09-02-2023
Expert Rev. Mol. Diagn., Volume 23, 2023, Issue 2
Clinical correlation of cadherin-17 marker with advanced tumor stages and poor prognosis of cholangiocarcinoma
01-02-2021
JSO, Volume 123, Issue 5, 1253-1262
Molecular diagnosis of hepatocellular carcinoma: trends in biomarkers combination to enhance early cancer detection
29-03-2019
Hepatoma Res 2019;5:9.
20517/2394-5079.2018.112
Roles of cadherin-17 in oncogenesis and therapeutic implications in liver cancer
03-12-2010
Biochim Biophys Acta. Cancer Rev. 2010 Dec; 1806(2):138-45

HKMA/HKT Global Innovation Award 2024/25 - Silver Award (SMEs)
23-01-2025

Compositions and Methods for detecting Cadherin-17 Protein (ELISA)
- WO2023060276A1
13-04-2023
Tibtech Methods and Compositions for Detecting CDH17 (IHC)
- WO2023060278A2
13-04-2023
Compositions and Methods for Diagnosing and Treating of Cancer
- WO219222557A1
21-11-2019

2024 Enterprise Support Scheme (ESS)
12-2024

Tiberias Technology, founded in 2016, is the sister company of Arbele Limited